STK11 and lung cancer: Previous reports on concurrent alterations in BRAF-mutant lung cancer, including V600 and non-V600 alterations, showed a higher rate of TP53 (53.3%), lower rate of STK11 (16.2%) and a similar rate of PIK3CA (6.6%), MYC (10.8%) and CDKN2A/B (11.2–16.6%) alterations [25], compared to our study (TP53 30%, STK11 16.2%, PIK3CA pathway 10%, MYC pathway 10% and cyclines pathway 10%).